SCHEMBL3439092

SCHEMBL3439092

CCN[C@@H](Cc1ccc(-c2cccc(N(C)C(=O)Nc3ccc4ccccc4c3)c2)cc1)C(=O)N1CCC(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.42
PLAU P00749 5/20 0.39
F10 P00742 3/20 0.39
OPRD1 P41143 1/20 0.39
PLG P00747 1/20 0.39
ST14 Q9Y5Y6 1/20 0.39
EPHX2 P34913 1/20 0.39
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
GAA P10253 2/20 0.38
FPR2 P25090 1/20 0.36
PIN1 Q13526 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PLAT P00750 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3439093 1.00 F2 (0.42) F2PLAUF10OPRD1PLG
SCHEMBL3439142 0.84 MME (0.44) GAANPC1RAB9AKDM4ELMNA
SCHEMBL3439010 0.81 PLG (0.37) F2PLAUF10PLGST14
SCHEMBL3439009 0.81 PLG (0.37) F2PLAUF10PLGST14
SCHEMBL3439001 0.79 MME (0.41) F2UBE2MDCUN1D1GAANPC1
SCHEMBL3439002 0.79 MME (0.41) F2UBE2MDCUN1D1GAANPC1
SCHEMBL3439123 0.77 MME (0.45) GAANPC1RAB9AKDM4ELMNA
SCHEMBL2083890 0.74 FFAR1 (0.50) GAANPC1RAB9AKDM4ELMNA
SCHEMBL3439126 0.73 PPARG (0.44)
SCHEMBL3439124 0.73 PPARG (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-03-05 US claimed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 US claimed
US-7807669-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-10-05 US disclosed
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-03-05 US disclosed
US-7452878-B2 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-11-18 US disclosed
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062340-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF PPARG, PPARA, PPARD F2 2300/4885PLAU 4024/4885F10 3921/4885
US-20050256116-A1 Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD F2 2300/4885PLAU 4024/4885F10 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.